Holen Sie sich die Stockscreener-App
1.56
1.89%
-0.03
Sonnet Biotherapeutics Holdings Inc Aktie (SONN) Neueste Nachrichten
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Corporate UpdateOn December 17, 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, released it - Defense World
Insights into Sonnet BioTherapeutics Q4 Earnings - Benzinga
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Slashes Operating Costs 37% in FY2024, Advances Cancer Drug Pipeline - StockTitan
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Sonnet BioTherapeutics (NASDAQ: SONN) Reports Positive Safety Data in SON-1010 Monotherapy Dose Escalation Trial - Defense World
Sonnet BioTherapeutics reports progress in cancer trial By Investing.com - Investing.com Nigeria
Sonnet BioTherapeutics reports progress in cancer trial - Investing.com India
Sonnet BioTherapeutics Announces $3.9 Million Registered - GlobeNewswire
Sonnet BioTherapeutics Secures $3.9M Strategic Financing Deal Through Mixed Securities Offering - StockTitan
Sonnet BioTherapeutics Announces Topline Safety Data - GlobeNewswire
Sonnet Bio's Cancer Drug Shows Promise: 48% Disease Control, One Patient's Tumor Shrinks 45% in Phase 1 Trial - StockTitan
Sonnet BioTherapeutics reports advances in cancer treatment drug By Investing.com - Investing.com Canada
Sonnet BioTherapeutics reports advances in cancer treatment drug - Investing.com India
Sonnet BioTherapeutics Announces Publication Detailing the - GlobeNewswire
Sonnet BioTherapeutics Unveils Breakthrough Cancer Drug Delivery System in Major Publication - StockTitan
Sonnet BioTherapeutics Holdings (STU:H3D) Financial Strengt - GuruFocus.com
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Sonnet BioTherapeutics’ $5 Million Common Stock Offering - Global Legal Chronicle
Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan
Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks
Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire
Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan
Dow Jumps Over 1,200 Points; Donald Trump Wins White House - Benzinga
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
When (SONN) Moves Investors should Listen - Stock Traders Daily
Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance - Stocks Telegraph
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance - TipRanks
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewswire
SONN (Sonnet BioTherapeutics Holdings) Capex-to-Operating-C - GuruFocus.com
Sonnet BioTherapeutics Enters into Licensing Agreement with Alkem Laboratories for DPN in India - Chemical Industry Digest
Alkem Labs inks pact with Sonnet BioTherapeutics to develop, commercialise drug candidate for diabetic... - Medical Dialogues
Alkem Labs partners with Sonnet BioTherapeutics to develop drug candidate for diabetic peripheral neuropathy in India - BSI bureau
Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India - The Financial Express
Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics - Equity Bulls
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):